Organization | Brickell Biotech, Inc.

Brickell Biotech, Inc. Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Miami FL United States (2009)

Status: Acquired by Vical (2019)

Organization Overview

First Clinical Trial

2014

NCT02058264

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Brickell Biotech, Inc.

Active Ingredients

Drugs in Phase 3 Trials (5)

Key: Brickell Biotech, Inc. (0) Acquired (5)

asp0113 (3 trials)

dacarbazine (dtic-dome) (2 trials)

sofpironium (8 trials)

temozolomide (temodar) (1 trial)

velimogene aliplasmid (allovectin) (5 trials)

Drugs in Phase 2 Trials (9)

Key: Brickell Biotech, Inc. (0) Acquired (9)

amphotericin b (fungizone) (1 trial)

isavuconazonium (cresemba) (1 trial)

leuvectin (2 trials)

phosphate-buffered saline (1 trial)

voriconazole (vfend) (1 trial)

Drugs in Phase 1 Trials (9)

Key: Brickell Biotech, Inc. (0) Acquired (9)

bbi-2000 (1 trial)

bbi-5000 (1 trial)

cmv vaccine (2 trials)

cymvectin (1 trial)

live, attenuated, dengue serotype 1, 2, 3, 4 virus (1 trial)

live tetravalent chimeric dengue vaccine (DENGVAXIA) (1 trial)

vcl-im01 (1 trial)

vcl-ipm1 (2 trials)

vcl-ipt1 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Dermatitis (Phase 1)

Dermatitis, Atopic (Phase 1)

Dermatitis, Contact (Phase 1)

Hyperhidrosis (Phase 3)

Overview

Highest Phase: None
# of Trials: 31
# of Trial APIs: 23